NCT06041841View on ClinicalTrials.gov

A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

4

Participants

Timeline

Start Date

December 31, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions

POMC Deficiency ObesityPCSK1 Deficiency ObesityLEPR Deficiency Obesity

Interventions

DRUG

LB54640

LB54640 QD Oral

Trial Locations (2)

Unknown

Pitié Salpêtrière hospital and Sorbonne Université, Paris

Cambridge university, Cambridge

Sponsors

Lead Sponsor

All Listed Sponsors

lead

LG Chem

INDUSTRY

NCT06041841 - A Phase 2 Study to Assess Efficacy and Safety of LB54640 in Patients With Genetic Obesity | Biotech Hunter | Biotech Hunter